Clinical Trial · NCT06101927

Molecular Imaging of Prostate-Specific Membrane Antigen Using Labeled Technetium-99m BQ0413

Overview

The study should evaluate the biological distribution of \[99mTc\]Tc-BQ0413 in patients with prostate cancer. The primary objective are: 1. To assess the distribution of \[99mTc\]Tc- BQ0413 in normal tissues and tumors at different time intervals. 2. To evaluate dosimetry of \[99mTc\]Tc- BQ0413. 3. To study the safety and tolerability of the drug \[99mTc\]Tc- BQ0413 after a single injection in a diagnostic dosage. The secondary objective are: 1\. To compare the obtained \[99mTc\]Tc- BQ0413 SPECT imaging results with the data of CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) studies in prostate cancer patients.

Sponsor

Tomsk National Research Medical Center of the Russian Academy of Sciences

Phase

Phase 1

Contacts

Vladimir I Chernov, MD,Prof (STUDY_DIRECTOR)

ClinicalTrials.gov

NCT06101927

Drug / Compound

BQ0413

Isotope(s):

Target(s):

PSMA

Ligand Class: Small Molecules

Chelator: mercaptoacetyl-triglutamate

Linker: 2-naphthyl-L-alanine and L-tyrosine

Eligibility

Inclusion

Clinical and radiological diagnosis of prostate cancer with histological verification.

Exclusion

Exclusion criteria not yet provided.